Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations

Department of Endocrinology and Metabolism, and the Department of Pharmacology, Hebrew University-Hadassah Medical School, Jerusalem Israel Research Division, Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School; and the Department of Medicine, Beth Israel Hospital Boston, Massachusetts Department of Anatomy, Case Western Reserve University Cleveland, Ohio

Cite This Article

Arie Gruzman, Gali Babai, Shlomo Sasson (2009). Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations. The Review of Diabetic Studies, 6(1), 13-36. https://doi.org/10.1900/rds.2009.6.13

Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations

You May Also Like